STAAR Surgical (NASDAQ:STAA) reported Q2 CY2025 revenue of $44.32 million, beating analyst estimates by 9.6%. However, sales fell by 55.2% year-on-year. The GAAP loss per share was $0.34, 49.9% higher than expected. The company designs and manufactures implantable lenses to correct vision problems. Over the past five years, STAAR Surgical has shown decent annualized revenue growth of 8.6%. Despite recent declines, analysts project a 44.4% revenue growth over the next 12 months. The company’s adjusted operating margin was negative 67.6% in the last quarter. EPS was negative $0.34, but analysts expect a break-even full-year EPS of negative $1.93.

Read more at stockstory.org is an independent website and not associated with a specific media company like Reuters, CBS MarketWatch, CNBC, Wall Street Journal, or Barchart.: STAAR Surgical (NASDAQ:STAA) Delivers Strong Q2 Numbers